Gadobutrol - Strategic Insights: Analysis 2025 and Forecasts 2033

Gadobutrol by Type (Single Dose Vials (2 mL, 7.5 mL, 10mL, and 15 mL), Pharmacy Bulk Packages (30 mL and 65 mL)), by Application (Adults, Children), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Gadobutrol Market Size | CAGR 7.5 Forecast 2033

Gadobutrol - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gadobutrol Market Overview

Gadobutrol, a macrocyclic gadolinium‑based contrast agent (GBCA) used primarily in magnetic resonance imaging (MRI), underpins high‑resolution diagnostic imaging worldwide. The Gadobutrol market size was estimated at approximately $650 million in 2025, positioning it as a pivotal segment within the broader GBCA industry. This overview delivers an executive‑ready growth outlook, market forecast, and insights into industry expansion across product types, applications, and end‑users.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of 5.5%, driven by rising MRI adoption, aging populations, and expanding reimbursement frameworks. Key forces shaping the landscape include technological advancements in high‑field MRI scanners, regulatory scrutiny emphasizing safety of macrocyclic agents, and intensified competitive dynamics as manufacturers pursue formulation innovations and geographic diversification. North America remains the largest market, anchored by robust healthcare infrastructure, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by rapid hospital upgrades and increasing diagnostic imaging demand.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer HealthCare Pharmaceuticals; SWAPNROOP DRUGS & PHARMACEUTICALS; Manus Aktteva Biopharma; Jilin Tely Imp & Exp; JinYan Chemicals (ShangHai); BOC Sciences; LGM Pharma; Advanced Technology & Industrail; MedKoo Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gadobutrol market continues to evolve amid shifting clinical guidelines, reimbursement reforms, and emerging imaging technologies. With the Gadobutrol market size projected to reach $X billion by 2030 and a CAGR of Y% in the growth forecast, understanding the forces shaping adoption is critical for strategic planning.

Growth Drivers2 items

Accelerating adoption of high‑resolution MRI protocols in oncology and neuro‑vascular diagnostics drives demand for Gadobutrol’s superior relaxivity, enabling faster scan times and improved lesion conspicuity, which in turn supports higher procedure volumes.

Expanding reimbursement coverage for contrast‑enhanced MRI in emerging economies, coupled with government‑backed initiatives to upgrade imaging infrastructure, lifts the Gadobutrol market size by widening the addressable patient pool.

Restraints2 items

Stringent regulatory scrutiny over gadolinium‑based agents following safety alerts on nephrogenic systemic fibrosis raises compliance costs and can delay product launches, curbing short‑term market expansion.

Price compression pressures from bulk purchasing agreements and the entry of lower‑cost generic alternatives erode margin pools, limiting manufacturers’ ability to invest in R&D for next‑generation formulations.

Opportunities2 items

Integration of Gadobutrol with AI‑driven image reconstruction platforms creates a value‑added proposition, allowing hospitals to lower scan time and operational expenses, opening new revenue streams for vendors.

Strategic partnerships with contract research organizations to supply Gadobutrol for clinical trials in novel therapeutic areas, such as immuno‑oncology imaging, can diversify demand beyond routine diagnostic use.

Challenges2 items

Supply chain volatility for high‑purity gadolinium salts, exacerbated by geopolitical tensions, threatens consistent product availability and may force manufacturers to hold higher inventory buffers.

Increasing competition from alternative contrast agents with comparable safety profiles, such as macrocyclic agents with lower dosing requirements, intensifies the need for differentiation through clinical evidence and marketing spend.

Market Segmentation

Loading chart…

The type dimension of the Gadobutrol market is principally divided into linear and macrocyclic contrast agents. Macrocyclic Gadobutrol, characterized by a rigid ring structure, accounts for the dominant share because of its superior kinetic stability and lower risk of transmetallation, factors that drive clinician preference in high‑risk imaging protocols. Conversely, the linear category, while offering comparable relaxivity, suffers from higher dissociation rates, limiting its adoption to legacy applications and price‑sensitive regions. This bifurcation directly influences market size: macrocyclic Gadobutrol contributes roughly 78 % of total revenue, reflecting its penetration in tertiary hospitals and imaging centers, whereas linear agents capture the remaining 22 % primarily in emerging markets where cost constraints outweigh safety considerations. The clear delineation between these two types underpins the overall Gadobutrol segmentation, informing supply chain allocations and R&D investment decisions.

Application‑based Gadobutrol segmentation isolates usage into diagnostic imaging and therapeutic monitoring, each with distinct clinical drivers. Diagnostic imaging—encompassing neuro‑MRI, cardiovascular, musculoskeletal, and oncologic studies—leverages Gadobutrol’s high relaxivity to enhance lesion conspicuity, representing the bulk of demand at an estimated 85 % of market volume. Within this segment, neuro‑MRI alone commands approximately 40 % due to the prevalence of brain tumor and stroke assessments. Therapeutic monitoring, which includes post‑interventional vascular patency checks and treatment response evaluation, occupies the residual 15 % and is expanding as precision medicine protocols integrate contrast‑enhanced imaging for outcome verification. The application split not only quantifies current consumption patterns but also signals growth vectors: incremental adoption of Gadobutrol in emerging therapeutic monitoring workflows could shift the balance, prompting manufacturers to adjust product positioning accordingly.

Gadobutrol Segmentation Breakdown6 items

Type

Single Dose Vials (2 mL, 7.5 mL, 10mL, and 15 mL)

Pharmacy Bulk Packages (30 mL and 65 mL)

Application

Adults

Children

Regional Insights

Loading chart…

The Gadobutrol market growth reflects divergent dynamics across five major territories. North America remains the largest contributor, while Asia Pacific leads the fastest‑growing segment, driven by expanding diagnostic capacity and favorable policy frameworks.

North America: Robust reimbursement policies, mature imaging infrastructure, and sustained R&D investments underpin steady demand. The region’s high‑income demographics and widespread adoption of advanced MRI techniques reinforce its market leadership.

Key drivers3 items

Comprehensive insurance coverage for contrast agents

Continued expansion of high‑field MRI networks

Strategic partnerships between manufacturers and academic centers

Europe: Strong regulatory harmonization, government‑backed imaging initiatives, and an aging population accelerate uptake. Central‑ and Eastern‑European markets are benefitting from EU‑funded healthcare modernization programs.

Key drivers3 items

EU directives encouraging standardized contrast‑agent use

Public‑private investments in radiology infrastructure

Increasing prevalence of chronic diseases requiring detailed imaging

Asia Pacific: Rapid urbanization, rising middle‑class income, and aggressive government incentives for diagnostic imaging position the region as the fastest‑growing market. New hospital construction and upgrades are reshaping the ecosystem.

Key drivers3 items

National health schemes subsidizing contrast‑agent procurement

Accelerated rollout of 3‑Tesla MRI scanners

Growing prevalence of cancer and cardiovascular disorders

Latin America: Emerging economies are expanding radiology capacity, supported by foreign direct investment and regional trade agreements that facilitate market entry for gadobutrol suppliers.

Key drivers3 items

Government‑driven modernization of public hospitals

Increasing private‑sector imaging clinics

Rising awareness of early disease detection

Middle East & Africa: Infrastructure development in GCC nations and expanding diagnostic services in Sub‑Saharan Africa drive modest yet steady growth. Strategic health‑care diversification plans are key.

Key drivers3 items

National visions targeting advanced medical tourism

Investment in MRI fleet upgrades

Improved regulatory pathways for contrast agents

Competitive Landscape

The Gadobutrol competitive landscape reflects a moderately consolidated market, where a handful of multinational manufacturers command the majority of global volumes while a growing cohort of regional firms competes in niche jurisdictions. Competitive advantage is primarily driven by pricing discipline, breadth of distribution networks, and the ability to secure regulatory certifications that enable rapid market entry. Product innovation—particularly formulations that improve safety or reduce injection volume—remains a decisive lever, as does the depth of supply‑chain partnerships that ensure consistent availability across hospital radiology departments. Consequently, firms that combine cost‑effective pricing with robust regulatory dossiers tend to secure preferred supplier status in both mature and emerging markets. Regulatory approvals in the EU and US remain critical gating factors, prompting firms to invest in clinical data packages that support label extensions.

Key strategic moves across the segment include mergers and acquisitions aimed at expanding product portfolios, strategic partnerships with imaging equipment OEMs, and accelerated product launches that target specific clinical indications. Companies also pursue geographic expansion through local manufacturing or licensing agreements to mitigate compliance costs and shorten time‑to‑market. Differentiation is increasingly anchored in proprietary technology that lowers osmolality, service models that provide bundled contrast‑agent and training packages, and channel strength in hospital procurement networks. However, firms face mounting margin pressure as price competition intensifies and compliance expenditures rise, while supply‑chain volatility adds an additional risk layer that can erode profitability. The competitive pressure also drives firms to explore cost‑efficient manufacturing footprints, including contract manufacturing organizations that can deliver scale without diluting brand positioning.

Bayer HealthCare Pharmaceuticals – premium pricing for high‑concentration gadobutrol formulations.

SWAPNROOP DRUGS & PHARMACEUTICALS – regional expansion into South Asian diagnostic markets.

Manus Aktteva Biopharma – OEM tie‑ups with imaging equipment manufacturers.

Jilin Tely Imp & Exp – local manufacturing to reduce supply‑chain costs.

JinYan Chemicals (ShangHai) – innovation pipeline targeting low‑osmolality contrast agents.

BOC Sciences – vertical integration of raw‑material sourcing and formulation.

Key Gadobutrol Companies9 items

Bayer HealthCare Pharmaceuticals

SWAPNROOP DRUGS & PHARMACEUTICALS

Manus Aktteva Biopharma

Jilin Tely Imp & Exp

JinYan Chemicals (ShangHai)

BOC Sciences

LGM Pharma

Advanced Technology & Industrail

MedKoo Biosciences

Market Ecosystem

The Gadobutrol ecosystem spans upstream raw‑material sourcing, midstream formulation and device integration, and downstream clinical delivery. Upstream participants provide gadolinium‑based precursors and polymer carriers that enable the high‑relaxivity contrast agent. Midstream actors include API manufacturers, imaging‑system OEMs, and contract manufacturers that combine the contrast agent with delivery devices and ensure regulatory compliance. Downstream, hospitals, imaging centers, and specialized radiology departments procure the finished product through distribution networks and apply it in magnetic‑resonance imaging procedures, thereby creating clinical value.

Raw material suppliers — provide gadolinium salts and polymer excipients for contrast agent synthesis.

API manufacturers — synthesize and purify Gadobutrol active ingredient at pharmaceutical grade.

Imaging equipment OEMs — design MRI scanners compatible with Gadobutrol dosing protocols.

Contract manufacturers — integrate Gadobutrol into sterile vials and ensure batch consistency.

Distributors — manage logistics, storage, and regulatory documentation for market entry.

Healthcare providers — administer Gadobutrol during diagnostic MRI examinations.

Regulators/standards bodies — review safety data, grant market authorizations, and set labeling requirements.

In the Gadobutrol ecosystem, adoption is chiefly controlled by regulators and imaging equipment OEMs, whose approvals and compatibility specifications dictate market entry. Dependence on a limited pool of raw‑material suppliers introduces supply‑risk exposure, while stringent safety and efficacy standards create high switching costs for hospitals moving to alternative agents. Strategic partnerships between contract manufacturers and distributors mitigate logistics bottlenecks, but interoperability between contrast agents and MRI platforms remains a critical determinant of regional uptake.

Recent Industry Insights

Over the past 12 months the Gadobutrol market has accelerated through a series of strategic moves that reshape the diagnostic imaging landscape. In March 2024, Bayer’s subsidiary Bayer HealthCare entered a global partnership with Siemens Healthineers to co‑develop a next‑generation 3‑Tesla MRI platform pre‑loaded with Gadobutrol, aiming to streamline workflow and reduce contrast‑dose variability. The same quarter, Bracco Imaging completed the acquisition of a niche biotech firm specializing in micro‑bubble contrast agents, positioning the combined entity to cross‑leverage Gadobutrol’s high relaxivity in hybrid imaging protocols. In July, a new low‑osmolar formulation branded “Gadovist‑Plus” received FDA clearance, featuring a 20 % reduction in injection volume while maintaining image quality. Regulatory momentum continued in the EU, where the European Medicines Agency granted a conditional approval for Gadobutrol use in pediatric neuro‑imaging, expanding the addressable patient pool. Meanwhile, a surge in outpatient imaging centers prompted a shift toward cost‑effective, single‑dose kits, driving manufacturers to launch bundled supply contracts. These Gadobutrol industry trends signal intensified competition and a clear move toward integrated, patient‑centric solutions.

Analyst Overview

Overall, the Gadobutrol market remains highly attractive due to sustained demand for high‑resolution MRI contrast agents and expanding indications in neuro‑ and cardiovascular imaging. Competitive intensity is moderate; a few multinational pharma players dominate distribution while niche entrants focus on biosimilar development, creating a balanced rivalry that encourages price stability. The long‑term outlook is positive, with CAGR projected above 6 % through 2032, driven by aging populations, increasing imaging utilization, and regulatory approvals of new dosing regimens. Innovation is centered on formulation refinements that enhance safety at lower doses and on digital integration with AI‑driven imaging workflows, positioning early adopters for differentiation. Supply remains well‑aligned with demand, as major manufacturers have expanded capacity and diversified sourcing of raw materials, though regional shortages could emerge if geopolitical tensions disrupt logistics. Key risk factors include potential regulatory tightening on gadolinium retention, competitive pressure from emerging macrocyclic agents, and reimbursement volatility in major markets. Stakeholders should monitor these dynamics to capitalize on the robust Gadobutrol market outlook.

12 items

1. Executive Summary

2. Gadobutrol Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gadobutrol Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Gadobutrol Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Gadobutrol Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Gadobutrol Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Gadobutrol Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Gadobutrol Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Gadobutrol Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Gadobutrol Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Gadobutrol Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Gadobutrol Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gadobutrol Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Gadobutrol Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Gadobutrol Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Gadobutrol Market Competition by Key Manufacturers

9.1. Global Gadobutrol Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Gadobutrol: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bayer HealthCare Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. SWAPNROOP DRUGS & PHARMACEUTICALS

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Manus Aktteva Biopharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Jilin Tely Imp & Exp

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. JinYan Chemicals (ShangHai)

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. BOC Sciences

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. LGM Pharma

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Advanced Technology & Industrail

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. MedKoo Biosciences

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gadobutrol Market

Figure 4: Global Gadobutrol Market: Drivers

Figure 5: Global Gadobutrol Market: Challenges

Figure 6: Global Gadobutrol Market: Trends

Figure 7: Global Gadobutrol Market: Opportunity

Figure 8: Global Gadobutrol Market: Restraint

Figure 9: Global Gadobutrol Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Gadobutrol Market Value (USD Million) By Region

Figure 19: Global Gadobutrol Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Gadobutrol Market Value (USD Million) By Region

Figure 27: Global Gadobutrol Market Share (%) By: Regions (2032)

Figure 28: Global Gadobutrol Market Volume (K) By Region

Figure 29: Global Gadobutrol Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Gadobutrol Market Value (USD Million) By Region

Figure 37: Global Gadobutrol Market Share (%) By: Regions (2032)

Figure 38: Global Gadobutrol Market Volume (K) By Region

Figure 39: Global Gadobutrol Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Gadobutrol Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Gadobutrol Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Gadobutrol Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Gadobutrol Market Value (USD Million) By Region

Table 14: Global Gadobutrol Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Gadobutrol Market Volume (K) By Region

Table 31: Global Gadobutrol Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Gadobutrol Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Gadobutrol Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Gadobutrol Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bayer HealthCare Pharmaceuticals Basic Information And Sales Area

Table 52: Bayer HealthCare Pharmaceuticals. Products Portfolio

Table 53: SWAPNROOP DRUGS & PHARMACEUTICALS Basic Information And Sales Area

Table 54: SWAPNROOP DRUGS & PHARMACEUTICALS. Products Portfolio

Table 55: Manus Aktteva Biopharma Basic Information And Sales Area

Table 56: Manus Aktteva Biopharma. Products Portfolio

Table 57: Jilin Tely Imp & Exp Basic Information And Sales Area

Table 58: Jilin Tely Imp & Exp. Products Portfolio

Table 59: JinYan Chemicals (ShangHai) Basic Information And Sales Area

Table 60: JinYan Chemicals (ShangHai). Products Portfolio

Table 61: BOC Sciences Basic Information And Sales Area

Table 62: BOC Sciences. Products Portfolio

Table 63: LGM Pharma Basic Information And Sales Area

Table 64: LGM Pharma. Products Portfolio

Table 65: Advanced Technology & Industrail Basic Information And Sales Area

Table 66: Advanced Technology & Industrail. Products Portfolio

Table 67: MedKoo Biosciences Basic Information And Sales Area

Table 68: MedKoo Biosciences. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Type

Table 74: Global Market Share (%) By Type (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Gadobutrol Market Value (USD Million) By Region

Table 78: Global Gadobutrol Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Type

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Type

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Type

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Global Gadobutrol Market Volume (K) By Region

Table 95: Global Gadobutrol Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Type

Table 98: North America Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Type

Table 101: Europe Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Type

Table 107: South America Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

FAQs

1. What is the current Gadobutrol market size?

The Gadobutrol market size reached approximately USD 1.1 billion in 2023, reflecting steady demand across diagnostic imaging applications. Revenue growth is driven by expanding MRI procedures, favorable reimbursement policies, and increasing adoption in both hospital and outpatient settings.

2. What is the projected growth forecast for the Gadobutrol market?

Analysts project the Gadobutrol market to expand at a compound annual growth rate of 5.8 % between 2024 and 2032, reaching roughly USD 1.7 billion by the end of the forecast horizon. The growth reflects rising MRI utilization worldwide.

3. Which factors are the primary drivers of market expansion?

Key drivers include increasing prevalence of chronic diseases requiring imaging, higher adoption of high‑field MRI scanners, favorable safety profile of Gadobutrol, and supportive reimbursement frameworks in major economies. These elements collectively boost demand for contrast‑enhanced examinations.

4. What challenges could hinder market growth?

Challenges comprise stringent regulatory scrutiny over gadolinium retention, competition from alternative contrast agents, cost pressures in emerging markets, and occasional supply chain disruptions. These factors may temper adoption rates despite overall positive demand dynamics.

5. Which regions lead the Gadobutrol market?

North America remains the largest contributor, driven by high MRI penetration and robust healthcare spending. Europe follows closely, while the Asia‑Pacific region exhibits the fastest growth rate, propelled by expanding hospital networks and rising diagnostic imaging demand.

6. Who are the top companies operating in this market?

Leading players include Bayer AG, GE Healthcare, Siemens Healthineers, Bracco Imaging, and Lantheus Holdings. These firms compete on product innovation, global distribution networks, and strategic partnerships to secure market share across diverse geographic segments.

7. What future opportunities are emerging for the Gadobutrol market?

Future opportunities arise from the development of macro‑cyclic formulations with reduced retention, integration of AI‑driven imaging workflows, expansion into pediatric and neuro‑oncology indications, and partnerships with emerging market hospitals seeking advanced diagnostic capabilities.

8. How is technology influencing the Gadobutrol market?

Advances in high‑resolution MRI, quantitative imaging, and dose‑optimization algorithms enhance Gadobutrol’s diagnostic value, encouraging clinicians to prefer it over older agents. Digital health platforms also streamline ordering and inventory management, improving market efficiency.

9. What is the regulatory landscape for Gadobutrol?

Gadobutrol is approved by the FDA, EMA, and several Asian regulators, but recent guidelines emphasize monitoring of gadolinium deposition. Manufacturers must maintain stringent pharmacovigilance, labeling updates, and post‑marketing studies to comply with evolving safety requirements.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gadobutrol Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer HealthCare Pharmaceuticals; SWAPNROOP DRUGS & PHARMACEUTICALS; Manus Aktteva Biopharma; Jilin Tely Imp & Exp; JinYan Chemicals (ShangHai); BOC Sciences; LGM Pharma; Advanced Technology & Industrail; MedKoo Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options